Dublin, Jan. 09, 2017 -- Research and Markets has announced the addition of the "Oncology Startups 2017" report to their offering.
Oncology Startups 2017, is the first unique attempt to provide highly precise and updated information on newly established cancer drug developing companies and enables their early identification.
The Report illuminates Top 500 cancer drug developers established during 2010-2016, and without any doubt is one of the world's largest focused data coverage on Active Drug Developers working with numerous methodologies to target cancer.
Oncology Startups 2017, is unique in many aspects as it for the first time provides cancer startups ranking, based on individual company's overall score on five major parameters- venture funding, key management, technology, deals & partnerships and cancer focused pipeline. The report, also provides quick infographics and final intelligence to keep information on fingertips.
Key Highlights:
- Startups Focused - Highly focused, includes only startups involved directly in Cancer Drug Discovery & established on and after 2010.
- Worldwide Geographic Coverage - Covers Top 500 startups from 28 countries, developing 628 cancer targeting therapies.
- Top 500 Ranking -For better, quicker and focused actionable intelligence on startups.
- Vast ImmunoOncology Coverage - Special Coverage, Infographics & Intelligence on 225 Top Emerging Immunooncology Startups.
- Technology / Drug Pipeline - Details on Individual Startup's proprietary Technologies with its Active Cancer Pipeline and University / Institutes Collaborations.
- Strategic Moves & Advantages- Quickly Identify the key strategic moves a startup is taking to be more innovative, also identify its strategic advantages, that will boost its growth going forward.
- Venture Funding / Partnering - Monitor Individual Startup's Various Funding Rounds (Private / Govt. ). Its current Partnering Status with CROs / Research Institutes / Big Pharma.
- Key Management Contacts - Big Time Saver - Key Management Details / Contacts / e-mails / LinkedIn ... all at one place
Finally, the report is based on selecting Top 500 Active Oncology Drug Developers, selected from over 700+ companies established during the duration. Also, report covers only active cancer targeting (treatment) companies excluding Merged, Dormant or Simply Idea based companies. The report does not includes cancer diagnostic and cancer pain management companies.
Oncology Startups 2017, will help various organizations working on cancer research, to supercharge with lots of new decision making information and jumpstart their current partnering/marketing efforts.
Key Topics Covered:
List of Top 500 Oncology Startup (Drug Developer) Companies
Section A :- Oncology Startups 2017 - Top 500 Active Drug Developers' Summary
Section B :- Oncology Startups 2017 - Venture Funding & Big Pharma Partnering & Deals with Startups
Section C :- Oncology Startups 2017 - Top 500 Companies Profiles
Appendix A: Country Wise List of Top 500 Oncology Startup Companies
Appendix B: Complete 628 Molecules List, along with their Developer's Name
Companies Mentioned
- AADI, LLC
- AB Initio Biotherapeutics, Inc.
- ABBA Therapeutics AG
- Accuronix Therapeutics, Inc.
- Acerta Pharma B.V
- ADC Therapeutics Sarl
- Adgero Biopharmaceuticals, Inc.
- Adheren, Inc.
- Adicet Bio, Inc.
- - AdiuTide Pharmaceuticals GmbH
- Aeglea BioTherapeutics Holdings LLC
- Affilogic
- Agalimmune Ltd.
- Agilvax, Inc.
- AiVita Biomedical, Inc.
- Akshaya Bio Inc.
- Alexo Therapeutics, Inc.
- Alissa Pharma LLC
- Allomek Therapeutics LLC
- AlloOnc Corporation
- Amal Therapeutics S.A.
- Amcure GmbH
- Amphivena Therapeutics, Inc.
- Andarix Pharmaceuticals, Inc.
- Annam Pharma, Inc.
and many more.
For more information about this report visit http://www.researchandmarkets.com/research/tglc3s/oncology_startups
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Business, Oncology


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Apple Turns 50: From Garage Startup to AI Crossroads
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



